Details of the Drug

General Information of Drug (ID: DMEV954)

Drug Name
Sulfinpyrazone
Synonyms
Anturan; Anturane; Anturanil; Anturano; Anturen; Anturidin; Diphenylpyrazone; Enturan; Enturen; Novopyrazone; Sulfinpirazona; Sulfinpyrazine; Sulfinpyrazon; Sulfinpyrazonum; Sulfoxyphenylpyrazolidin; Sulfoxyphenylpyrazolidine; Sulphinpyrazone; Apo Sulfinpyrazone; Apotex Brand of Sulfinpyrazone; Novartis Brand of Sulfinpyrazone; Nu Pharm Brand of Sulfinpyrazone; Nu Sulfinpyrazone; G 28315; Anturane (TN); Apo-Sulfinpyrazone; G 28,315; Nu-Pharm Brand of Sulfinpyrazone; Nu-Sulfinpyrazone; Sulfinpirazona [INN-Spanish]; Sulfinpyrazone (SPZ); Sulfinpyrazonum [INN-Latin]; USAF GE-13; Sulfinpyrazone [USAN:INN:JAN]; Sulfinpyrazone (JP15/USP/INN); (+/-)-SULFINPYRAZONE; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin; 1,2-Diphenyl-3,5-dioxo-4-(2'-phenyl-sulfinyl-aethyl)-pyrazolidin [German]; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl) pyrazolidine; 1,2-Diphenyl-3,5-dioxo-4-(2-phenylsulfinylethyl)pyrazolidine; 1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione; 1,2-Diphenyl-4-[2-(phenylsulfinyl)ethyl-3,5-pyrazolidinedione; 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione; 4-(2-Benzenesulfinylethyl)-1,2-diphenylpyrazolidine-3,5-dione; 4-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione; 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
Indication
Disease Entry ICD 11 Status REF
Gout FA25 Approved [1], [2], [3]
Therapeutic Class
Uricosuric Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 404.5
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.34 mL/min/kg [6]
Elimination
39% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 6 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 28.254 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.017% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.12 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.031 mg/mL [4]
Chemical Identifiers
Formula
C23H20N2O3S
IUPAC Name
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
Canonical SMILES
C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
InChI
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5342
ChEBI ID
CHEBI:9342
CAS Number
57-96-5
DrugBank ID
DB01138
TTD ID
D03DEI
VARIDT ID
DR00513
INTEDE ID
DR1515

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Multidrug resistance-associated protein 1 (ABCC1) TTOI92F MRP1_HUMAN Modulator [8], [9], [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Gout
ICD Disease Classification FA25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Multidrug resistance-associated protein 1 (ABCC1) DTT ABCC1 1.01E-02 0.89 1.34
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 9.91E-01 -4.05E-02 -1.15E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.13E-01 6.17E-02 2.28E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.96E-01 -3.35E-01 -1.10E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sulfinpyrazone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Increased metabolism of Sulfinpyrazone caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [43]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Sulfinpyrazone caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [44]
Oliceridine DM6MDCF Moderate Increased metabolism of Sulfinpyrazone caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [45]
Ivabradine DM0L594 Moderate Increased metabolism of Sulfinpyrazone caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [46]
Dronedarone DMA8FS5 Moderate Increased metabolism of Sulfinpyrazone caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [47]
Bedaquiline DM3906J Moderate Increased metabolism of Sulfinpyrazone caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [48]
Cariprazine DMJYDVK Moderate Increased metabolism of Sulfinpyrazone caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [46]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Sulfinpyrazone caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Lapatinib DM3BH1Y Moderate Increased metabolism of Sulfinpyrazone caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
LY2835219 DM93VBZ Moderate Increased metabolism of Sulfinpyrazone caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Sulfinpyrazone caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Palbociclib DMD7L94 Moderate Increased metabolism of Sulfinpyrazone caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
Alpelisib DMEXMYK Moderate Increased metabolism of Sulfinpyrazone caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Sulfinpyrazone caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Macitentan DMP79A1 Moderate Increased metabolism of Sulfinpyrazone caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [55]
PF-04449913 DMSB068 Moderate Increased metabolism of Sulfinpyrazone caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [56]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Levomilnacipran. Chronic pain [MG30] [57]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Sulfinpyrazone and Regorafenib. Colorectal cancer [2B91] [46]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Intedanib. Colorectal cancer [2B91] [58]
Drospirenone DM1A9W3 Moderate Increased metabolism of Sulfinpyrazone caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [52]
Ulipristal DMBNI20 Moderate Increased metabolism of Sulfinpyrazone caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [46]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Sulfinpyrazone and Ardeparin. Coronary thrombosis [BA43] [59]
Ivacaftor DMZC1HS Moderate Increased metabolism of Sulfinpyrazone caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [60]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Sulfinpyrazone and Rivaroxaban. Deep vein thrombosis [BD71] [61]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Vilazodone. Depression [6A70-6A7Z] [57]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Vortioxetine. Depression [6A70-6A7Z] [57]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Milnacipran. Depression [6A70-6A7Z] [57]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Escitalopram. Depression [6A70-6A7Z] [57]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Desvenlafaxine. Depression [6A70-6A7Z] [57]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Clomipramine. Depression [6A70-6A7Z] [57]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Sulfinpyrazone caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [62]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Sulfinpyrazone and Apigenin. Discovery agent [N.A.] [63]
Stiripentol DMMSDOY Moderate Increased metabolism of Sulfinpyrazone caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Sulfinpyrazone caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [64]
Solifenacin DMG592Q Moderate Increased metabolism of Sulfinpyrazone caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [65]
Mirabegron DMS1GYT Minor Increased metabolism of Sulfinpyrazone caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [66]
Ripretinib DM958QB Moderate Increased metabolism of Sulfinpyrazone caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [50]
Sunitinib DMCBJSR Moderate Increased metabolism of Sulfinpyrazone caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [50]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Sulfinpyrazone and Avapritinib. Gastrointestinal stromal tumour [2B5B] [46]
MK-1439 DM215WE Moderate Increased metabolism of Sulfinpyrazone caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Sulfinpyrazone caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Fostemsavir DM50ILT Minor Increased metabolism of Sulfinpyrazone caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Cobicistat DM6L4H2 Moderate Increased metabolism of Sulfinpyrazone caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Dolutegravir DMCZGRE Minor Increased metabolism of Sulfinpyrazone caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [71]
Saquinavir DMG814N Moderate Increased metabolism of Sulfinpyrazone caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Elvitegravir DMG9B1U Moderate Increased metabolism of Sulfinpyrazone caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Etravirine DMGV8QU Moderate Increased metabolism of Sulfinpyrazone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [72]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Sulfinpyrazone caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Darunavir DMN3GCH Moderate Increased metabolism of Sulfinpyrazone caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Maraviroc DMTL94F Moderate Increased metabolism of Sulfinpyrazone caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [50]
Tolvaptan DMIWFRL Moderate Increased metabolism of Sulfinpyrazone caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [46]
Lesinurad DMUR64T Moderate Decreased metabolism of Sulfinpyrazone caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [73]
Suvorexant DM0E6S3 Moderate Increased metabolism of Sulfinpyrazone caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Sulfinpyrazone caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [75]
Naloxegol DML0B41 Moderate Increased metabolism of Sulfinpyrazone caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [76]
Crizotinib DM4F29C Moderate Increased metabolism of Sulfinpyrazone caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [77]
Brigatinib DM7W94S Moderate Increased metabolism of Sulfinpyrazone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [50]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Sulfinpyrazone caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [78]
Osimertinib DMRJLAT Moderate Increased metabolism of Sulfinpyrazone caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [79]
Capmatinib DMYCXKL Moderate Increased metabolism of Sulfinpyrazone caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
Artemether DM48QOT Moderate Increased metabolism of Sulfinpyrazone caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [50]
Idelalisib DM602WT Moderate Increased metabolism of Sulfinpyrazone caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [81]
GDC-0199 DMH0QKA Moderate Increased metabolism of Sulfinpyrazone caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
IPI-145 DMWA24P Moderate Increased metabolism of Sulfinpyrazone caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Sulfinpyrazone and Acalabrutinib. Mature B-cell lymphoma [2A85] [84]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Sulfinpyrazone and Ibrutinib. Mature B-cell lymphoma [2A85] [85]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Sulfinpyrazone and Ponatinib. Mature B-cell lymphoma [2A85] [86]
Vemurafenib DM62UG5 Moderate Increased metabolism of Sulfinpyrazone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [87]
LGX818 DMNQXV8 Moderate Increased metabolism of Sulfinpyrazone caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [88]
Flibanserin DM70DTN Moderate Increased metabolism of Sulfinpyrazone caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [89]
Panobinostat DM58WKG Moderate Increased metabolism of Sulfinpyrazone caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [90]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Sulfinpyrazone caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [91]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Sulfinpyrazone and Dasatinib. Myeloproliferative neoplasm [2A20] [92]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Sulfinpyrazone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [93]
Rolapitant DM8XP26 Moderate Increased metabolism of Sulfinpyrazone caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [94]
E-2007 DMJDYNQ Moderate Increased metabolism of Sulfinpyrazone caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [46]
Entrectinib DMMPTLH Moderate Increased metabolism of Sulfinpyrazone caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [46]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Nepafenac. Osteoarthritis [FA00-FA05] [95]
Olaparib DM8QB1D Moderate Increased metabolism of Sulfinpyrazone caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [50]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and MK-4827. Ovarian cancer [2C73] [46]
Pimavanserin DMR7IVC Moderate Increased metabolism of Sulfinpyrazone caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [96]
Macimorelin DMQYJIR Moderate Increased metabolism of Sulfinpyrazone caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [97]
Lefamulin DME6G97 Moderate Increased metabolism of Sulfinpyrazone caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [98]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Sulfinpyrazone caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [99]
Enzalutamide DMGL19D Moderate Increased metabolism of Sulfinpyrazone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [100]
Darolutamide DMV7YFT Moderate Increased metabolism of Sulfinpyrazone caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [101]
Silodosin DMJSBT6 Moderate Increased metabolism of Sulfinpyrazone caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [50]
Apremilast DMTWS9E Moderate Increased metabolism of Sulfinpyrazone caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [102]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Epoprostenol. Pulmonary hypertension [BB01] [103]
Riociguat DMXBLMP Moderate Increased metabolism of Sulfinpyrazone caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [104]
Everolimus DM8X2EH Moderate Increased metabolism of Sulfinpyrazone caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [50]
Axitinib DMGVH6N Moderate Increased metabolism of Sulfinpyrazone caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [105]
Temsirolimus DMS104F Moderate Increased metabolism of Sulfinpyrazone caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [50]
Tofacitinib DMBS370 Moderate Increased metabolism of Sulfinpyrazone caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [50]
Quetiapine DM1N62C Moderate Increased metabolism of Sulfinpyrazone caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [50]
Aripiprazole DM3NUMH Moderate Increased metabolism of Sulfinpyrazone caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [106]
LDE225 DMM9F25 Moderate Increased metabolism of Sulfinpyrazone caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [107]
Larotrectinib DM26CQR Moderate Increased metabolism of Sulfinpyrazone caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [50]
Docetaxel DMDI269 Moderate Increased metabolism of Sulfinpyrazone caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [108]
Trabectedin DMG3Y89 Moderate Increased metabolism of Sulfinpyrazone caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [46]
Armodafinil DMGB035 Moderate Increased metabolism of Sulfinpyrazone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [109]
LEE011 DMMX75K Moderate Increased metabolism of Sulfinpyrazone caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [50]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Sulfinpyrazone and Curcumin. Solid tumour/cancer [2A00-2F9Z] [110]
Taxol DMUOT9V Moderate Increased metabolism of Sulfinpyrazone caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Fostamatinib DM6AUHV Moderate Increased metabolism of Sulfinpyrazone caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [69]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Sulfinpyrazone and Cangrelor. Thrombosis [DB61-GB90] [112]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Sulfinpyrazone and Brilinta. Thrombosis [DB61-GB90] [46]
Saxagliptin DMGXENV Moderate Increased metabolism of Sulfinpyrazone caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [113]
Linagliptin DMWFJTR Moderate Increased metabolism of Sulfinpyrazone caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [114]
Elagolix DMB2C0E Moderate Increased metabolism of Sulfinpyrazone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [115]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Sulfinpyrazone and Betrixaban. Venous thromboembolism [BD72] [112]
⏷ Show the Full List of 111 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5826).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011556.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40.
9 Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of o... J Biol Chem. 2001 May 11;276(19):15616-24.
10 Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q. Genomics. 1999 Sep 15;60(3):295-308.
11 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
12 CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):795-804.
13 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
24 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
25 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
26 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
27 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
28 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
29 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
30 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
31 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
32 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
33 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
34 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
35 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
36 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
37 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
38 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
39 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
40 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36.
41 Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62.
42 Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4967-72.
43 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
44 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
45 Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
46 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
47 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
48 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
49 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
50 Cerner Multum, Inc. "Australian Product Information.".
51 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
52 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
53 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
55 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
56 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
58 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
59 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
60 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
61 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
62 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
63 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
64 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
65 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
66 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
67 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
68 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
69 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
70 Canadian Pharmacists Association.
71 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
72 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
73 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
74 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
75 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
76 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77 Cerner Multum, Inc. "Canadian Product Information.".
78 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
79 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
80 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
82 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
83 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
84 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
85 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
86 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
87 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
88 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
89 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
90 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
91 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
92 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
93 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
94 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
95 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
96 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
97 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
98 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
99 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
100 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
101 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
102 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
103 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
104 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
105 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
106 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
107 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
108 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
109 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
110 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
111 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
112 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
113 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
114 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
115 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.